About Us

Clyde Biosciences is a leading global cardiac safety service provider. Our speciality is in the assessment of cardiotoxicity potential for the global pharmaceutical industry. We work with:
  • Safety Pharmacology
  • Cardiovascular Therapeutics
  • Leading Stem Cell Suppliers
Our technology was developed in the laboratory of Professor Godfrey Smith (Chief Scientific Officer, Clyde Biosciences) a world-leading cardiac scientist with 25+ years experience in cardiac electrophysiology research. Clyde’s CellOPTIQ® platform delivers reliable, high resolution functional output from a range of cardiac cell types including iPS-derived heart cells. High bandwidth membrane voltage signals from CellOPTIQ® provides new insights into electrophysiological effects of drugs. Rapid data capture and analysis is made possible by our bespoke software which allows accelerated assay throughput in a 96 well format.